JEMPERLI
500mg/10mlJEMPERLI500mg/10ml
JEMPERLI (Dostarlimab) 500mg/10ml is a humanized anti-PD-1 monoclonal antibody for dMMR/MSI-H endometrial cancer and solid tumors.
Key Benefits
- 100% complete response in dMMR rectal cancer (NEJM landmark study)
- FDA-approved for dMMR endometrial cancer and solid tumors
- Convenient every-6-week maintenance dosing
- Tissue-agnostic approval for dMMR/MSI-H tumors
- Potential to eliminate need for surgery in select dMMR cancers
Contact Us for Pricing
Get a written quote against a prescription within 24 hours for JEMPERLI 500mg/10ml. Our team is available 24/7.
Direct line: +44 7429 917553
Prescription required
We do not proceed without one
Licensed Türkiye channels
İTS serial-traceable by karekod
Delivered in person
Not shipped by courier
Written reply
Quote within 24 hours
How JEMPERLI Works
Dostarlimab binds to the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 ligands on tumor cells. This prevents the cancer's immune evasion mechanism and restores anti-tumor T cell activity, allowing the immune system to recognize and destroy cancer cells.
About JEMPERLI 500mg/10ml
JEMPERLI (Dostarlimab-gxly) 500mg/10ml by GlaxoSmithKline (GSK) is a breakthrough anti-PD-1 checkpoint inhibitor that gained worldwide recognition after achieving 100% complete response in dMMR rectal cancer patients in a landmark NEJM study. FDA-approved for dMMR recurrent or advanced endometrial cancer and dMMR solid tumors, Jemperli represents a potential paradigm shift in precision oncology. Its unique every-6-week maintenance dosing schedule offers significant convenience over other checkpoint inhibitors. Working through licensed Turkish pharmacy channels, we provide authentic GSK JEMPERLI with complete cold chain handling, batch and expiry documentation, and a written quote against a prescription, usually within 24 hours for hospitals, oncology centers, and pharmaceutical distributors worldwide.
Common Uses
- dMMR recurrent or advanced endometrial cancer
- dMMR recurrent or advanced solid tumors (tissue-agnostic)
- dMMR locally advanced rectal cancer (investigational, 100% CR)
- MSI-H solid tumors after prior therapy
Dosage Information
Doses 1-4: 500mg IV over 30 min every 3 weeks. Dose 5 onwards: 1000mg IV every 6 weeks. Requires dMMR/MSI-H biomarker confirmation. Continue until disease progression or unacceptable toxicity.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. After dilution in 0.9% NaCl or 5% Dextrose: stable 24 hours at 2-8°C or 6 hours at room temperature including infusion.
We ensure proper cold chain handling during shipping to maintain product integrity.
Full prescribing monograph
A single reference page compiled from the manufacturer's prescribing information and the regulator's public product data. No pricing is published on it.
Frequently Asked Questions About JEMPERLI
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
